Upregulation of endogenous prostaglandins to lower intraocular pressure
US6376541B1 · kind B1 · utility
109Cited by
8References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 6, 1999 |
| Grant date | Apr 23, 2002 |
| Priority date | — |
| Expiry date | Dec 6, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of lowering intraocular pressure (IOP) employs an upregulating agent that induces increased prostaglandin synthesis in the eye. The method of treatment entails administering to the eye of a mammal in need thereof a prostaglandin upregulating agent to increase endogenous prostaglandin synthesis and thereby effect a reduction in intraocular pressure. In a preferred embodiment the upregulating agent is IL-1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.